The current pharma tariffs are based on a "national security provision" (Section 232), which has a more secure legal footing than prior, successfully challenged tariff orders. Drawing parallels to long-standing steel and China tariffs, companies should strategize for this as a permanent feature of the trade landscape, not a temporary policy.

Looming pharma tariffs lack clear guidance, creating chaos for the industry. However, this uncertainty primarily impacts small and mid-sized companies reliant on overseas manufacturing. Larger pharmaceutical companies have already negotiated exemptions through specific deals, creating a two-tiered system of risk.

The proposal to levy tariffs and then issue rebate checks is economically nonsensical. It creates massive bureaucratic leakage, making it more efficient to simply not have the tariffs. Furthermore, the policy uncertainty paralyzes businesses, creating non-economic costs that are more damaging than the direct financial impact of the tariffs.

The most crippling aspect of the ongoing tariff saga is the uncertainty it creates. The inability for businesses, especially small ones, to conduct long-term planning due to unpredictable policy shifts is more economically damaging than the direct financial cost of the duties.

The administration's proposed 100% tariffs on some pharma companies are more political posturing than substantive policy. The tariffs exclude generics, orphan drugs, and rare disease treatments. Additionally, 16 of the 17 largest pharma companies have already signed deals with the U.S., making them exempt.

After intense scenario analysis during initial tariff announcements, life sciences companies have developed templates to manage trade policy risks. This preparedness has demoted tariffs from a major strategic driver to a manageable operational factor, allowing M&A to proceed with less hesitation.

The proposed pharma tariffs include a key loophole: the Secretary of Commerce can exempt any product by designating it a "specialty drug." This subjective clause opens the door for political influence, cronyism, and intense lobbying to secure exemptions, adding a layer of political risk for companies.

Unlike large firms making US investment pledges for exemptions, smaller drug makers must rely on nuanced, capital-light tactics. These include unbundling costs to lower dutiable value, using duty drawback programs for re-exported goods, and leveraging foreign trade zones to survive high tariff rates without massive infrastructure spending.

The proposed pharma tariffs exempt companies with MFN (Most Favored Nation) deals, which are primarily large players. This gives them a strategic advantage in M&A, as they can acquire smaller, tariff-burdened companies and absorb their assets into a tariff-free structure, creating favorable deal dynamics.